HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Jan. 19, 2006--Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that recent studies have shown that the Company’s AlzheimAlert(TM) test can be useful in the clinical evaluation of the earliest stages of Alzheimer’s disease (AD). AlzheimAlert(TM) is Nymox’s proprietary test which measures urinary levels of neural thread protein (NTP), which is elevated in AD. As part of a broad range of studies investigating the utility of the AlzheimAlert(TM) technology, individuals with mild cognitive impairment (MCI) have been found to have significant findings in their AlzheimAlert(TM) test results. MCI is believed to be the earlier recognizable stage of the evolution of AD. Results from the independently undertaken MCI studies of AlzheimAlert(TM) will be presented at national and international meetings this year, and published in the medical literature in due course.
